Pharmaceutical CDMO Ardena (Gent, Belgium) announce the expansion of its capacity for purification and fractionation at its site in Södertälje (Sweden) to aid Novavax (MD, USA) in the long-term production of their COVID-19 vaccine.
Following conditional marketing authorization granted by the European Commission, Novavax’s COVID-19 vaccine, termed Nuvaxovid, will be the fifth vaccine approved for utilization in Europe. As a recombinant protein-based vaccine, Ardena’s expansion will satisfy Novavax’s demand for chromatographic capabilities, tangential flow filtration and lyphilization capabilities. Ardena has been a partner of Novavax for 15 years for the development of a fractionation process for Matrix-M™, a key adjuvant in Nuvaxovid to enhance immune response against the SARS-CoV-2 virus.
[ui-btn url=”https://www.bioanalysis-zone.com/expansion-of-ardena-development-and-manufacturing-site-to-aid-in-covid-19-vaccine-development-by-novavax/” text=”READ MORE ON BIOANALYSIS ZONE NOW” target=”_blank”][/ui-btn]
Powered by WPeMatico